. 2023 Jan 20;28(1):2160569. doi: 10.1080/13510002.2022.2160569

Table 3.

Serum lipid profile among studied groups.

Parameters	Control (n = 15)	PCOS-IR (n = 12)	MET (n = 12)	SeNPs (n = 12)	SeNPs + MET (n = 12)
TG (mg/dL)	61.68 ± 6.18	107.37 ± 4.47^a^,^c^,^d^,^e	87.12 ± 2.92^a^,^b^,^e	83.72 ± 6.81^a^,^b	64.11 ± 3.82^b^,^c
TC (mg/dL)	83.55 ± 5.21	134.89 ± 6.43^a^,^c^,^d^,^e	98.52 ± 2.67^a^,^b	102.64 ± 4.22^a^,^b	96.45 ± 3.51^a^,^b
HDL-C (mg/dL)	52.61 ± 6.37	23.14 ± 3.45^a^,^c^,^d^,^e	42.53 ± 5.16^a^,^b	39.33 ± 5.71^a^,^b	48.61 ± 3.08^a^,^b
LDL-C (mg/dL)	22.31 ± 4.52	90.43 ± 2.54^a^,^c^,^d^,^e	39.23 ± 2.85^a^,^b	47.37 ± 4.24^a^,^b	35.25 ± 2.79^a^,^b

Data were expressed as mean ± SD, ^aSignificant change vs. control, ^bSignificant change vs. PCOS-IR, ^cSignificant change vs. MET, ^dSignificant change vs. SeNPs, ^eSignificant change vs SeNPs + MET. PCOS, Polycystic ovarian syndrome; MET, Metformin; SeNPs, Selenium nanoparticles. IR, insulin Resistance; TG, triacylglycerol; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.